Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court Ruling On Pfizer Price Hikes Could Delay Other Investigations, Warns UK Competition Authority

Executive Summary

Ongoing Investigations into drug price increases could be at risk following a tribunal ruling in the UK phenytoin sodium case, according to the Competition and Markets Authority, which is considering an appeal against the judgment.

Advertisement

Related Content

Will Recent Excessive Pricing Cases Lay Down Precedent For Future?
Will Recent Excessive Pricing Cases Lay Down Precedent For Future?
Pharma Cases Show How Brexit Could Hit Alignment Of UK & EU Competition Law
Concordia Names Six Drugs Targeted By UK Competition Inquiry
Rash of Generic Price Hikes Pushes UK Health Dept Into Action
Rash of Generic Price Hikes Pushes UK Health Dept Into Action
UK Competition Body Backs Up Claim That Pfizer & Flynn Abused Dominant Position With ‘Excessive’ Prices
UK Fine For Pfizer/Flynn’s ‘Excessive And Unfair’ Pricing Sends Clear Message To Others

Topics

Advertisement
UsernamePublicRestriction

Register

PS123259

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel